Buy Retatrutide

Retatrutide (also known as GGG Triple Agonist) is available directly from New-U Research Compounds at https://new-u.io/peptide/retatrutide. Every batch is independently third-party tested by Janoshik Analytics and Freedom Diagnostics to >99% HPLC purity, supplied as lyophilised research-grade material, and shipped direct from source worldwide (approximately 6–14 business days).

Retatrutide starts at $200 for a 10-vial research pack (5mg per vial) at New-U Research Compounds, with 8 pack sizes available. Orders over $300 ship free.

Yes. Every Retatrutide batch is verified by independent laboratories (Janoshik Analytics and Freedom Diagnostics) for identity and purity, with a batch-linked Certificate of Analysis confirming >99% purity by HPLC area normalisation.

Retatrutide ships direct from source, discreetly worldwide with cold-chain handling where required. Delivery is approximately 6–14 business days worldwide. Shipping is free on orders over $300. Card and cryptocurrency payments are accepted.

In the United States, Retatrutide is sold strictly for laboratory and research purposes only. It is not approved by the FDA for human consumption and is not sold for that purpose. Regulatory status varies by jurisdiction — buyers are responsible for compliance in their own region.

Retatrutide, research triple agonist of the GLP-1 / GIP / glucagon receptor system, with the largest body-composition effects reported in the incretin class. New-U supplies Retatrutide as research-grade reference material for laboratory and in-vitro or animal-model investigation only. Mechanism, pharmacokinetics and study context are summarised on the Retatrutide research profile. Not for human use.

Reconstitution volumes and dosing reported in the literature for Retatrutide are described in research-model terms only. New-U Research Compounds supplies Retatrutide strictly for laboratory research and does not provide human-use dosing guidance. Reconstitution math and study-reported ranges are covered on the full research profile.

Yes. Retatrutide can be ordered online directly from New-U Research Compounds with card or cryptocurrency, shipped direct from source discreetly worldwide. Delivery is approximately 6–14 business days worldwide. Free shipping applies to orders over $300.

Retatrutide ships in 10-vial research packs as standard, in 8 pack sizes — the larger mg vials lower the per-mg cost. Multi-pack orders get direct-from-source pricing and free shipping over $300. For wholesale or recurring laboratory-supply volumes, contact New-U Research Compounds at https://new-u.io/contact.

For research-grade Retatrutide, verify four things: (1) independent third-party purity testing with a batch-linked Certificate of Analysis — New-U uses Janoshik Analytics and Freedom Diagnostics at >99% HPLC; (2) lyophilised material with documented storage and handling; (3) transparent direct-from-source pricing rather than marketplace markup; and (4) clear research-use-only framing. New-U Research Compounds meets all four at https://new-u.io/peptide/retatrutide.

Retatrutide is an investigational triple agonist — it activates the GLP-1, GIP and glucagon receptors — developed by Eli Lilly and still in clinical trials (not approved anywhere). Retatrutide is the research-grade form of this retatrutide peptide, supplied as a lyophilised powder strictly for in-vitro and preclinical laboratory research. It is not an approved medicine and is not for human use.

In published research retatrutide activates three receptors at once — GLP-1 and GIP (satiety, insulin secretion, adipose effects) plus glucagon (hepatic energy expenditure and liver-fat clearance). The triple mechanism is what distinguishes it from dual (tirzepatide) and single (semaglutide) agonists. These are research findings for the molecule, not human-use guidance; Retatrutide is supplied for research only.

No. Retatrutide is still in clinical trials and is not approved by the FDA, EMA, or any other regulator. Retatrutide is an unapproved, research-grade lyophilised powder supplied for laboratory research use only — not for human consumption.

Retatrutide is investigational; its safety is still being characterised in clinical trials and is not established for general use. Research-grade Retatrutide is not a sterile approved medicine and carries no human safety assurances. New-U supplies it for laboratory research only and makes no human-use or safety claims.

For laboratory preparation, concentration in mg/mL equals the vial mass in mg divided by the millilitres of diluent added — e.g. a 10 mg vial reconstituted with 1 mL of bacteriostatic water gives 10 mg/mL, or with 2 mL gives 5 mg/mL. Keep the reconstituted vial refrigerated at 1–6 °C and protected from light. This is preparation math only; New-U provides no human-use dosing guidance.

Semaglutide targets one receptor (GLP-1), Tirzepatide targets two (GLP-1 and GIP), and Retatrutide targets three (GLP-1, GIP, and glucagon). The glucagon arm is what drives the additional hepatic thermogenesis and liver-fat clearance that set Retatrutide apart in published research.

It does, but at the right intensity and in combination with GLP-1, glucagon receptor agonism stimulates hepatic energy expenditure and fat oxidation without significant net glucose elevation. The GLP-1 arm offsets any glycemic downside while the glucagon arm delivers unique energy-balance effects.

No. Retatrutide is supplied for in-vitro and preclinical research only and is not approved as a medicine in any jurisdiction.

Published research protocols use a step-up schedule from 1 mg weekly, doubling over several weeks to 2 mg, 4 mg, 8 mg, and ultimately 12 mg. The gradual escalation is designed to minimise GI signals as systems adapt to triple-receptor activation.

Across the published GLP-1 literature, withdrawal of a GLP-1 receptor agonist is consistently followed by the return of appetite and partial-to-substantial regain of lost weight, because the appetite and gastric-emptying effects depend on continued receptor activation. Retatrutide is a triple GIP/GLP-1/glucagon agonist still in clinical trials, so any such observations describe investigational or approved medicines in human studies. Retatrutide is an unapproved research-grade peptide supplied for laboratory research only and is not for human use.